Patrick Hwu: I had a great listening tour this week with our PRMS and Regulatory Affairs teams at Moffitt Cancer Center

Patrick Hwu shared on X:

“I had another great listening tour this week with our PRMS (Protocol Review and Monitoring System) and Regulatory Affairs teams at Moffitt Cancer Center.

These teams are responsible for reviewing the scientific merit, feasibility, priority, progress and regulatory oversight of clinical trials.

Clinical trials provide patients with therapies not yet available as standard of care, and are often a patient’s best chance at the best outcome.

As such, this team’s work is an important part of our mission to contribute to the prevention and cure of cancer!”

Source: Patrick Hwu/X

Dr. Patrick Hwu, MD, currently serves as the President and CEO of Moffitt Cancer Center. With a focus on understanding the dynamics between tumors and the immune system, Dr. Hwu’s research has been pivotal in advancing gene-modified T cell therapy.

He notably contributed seminal work on the development of the first chimeric antigen receptor aimed at combating cancer. His research portfolio extends to vaccines, adoptive T-cell therapies, and mechanisms of immune resistance.